Title: Mirabegron: potential off target effects and uses beyond the bladder.
Journal: British journal of pharmacology 20181101
Title: Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
Journal: Chemical research in toxicology 20150518
Title: The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option.
Journal: Expert opinion on drug metabolism & toxicology 20130501
Title: Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.
Journal: International journal of clinical pharmacology and therapeutics 20121101
Title: Use of mirabegron in treating overactive bladder.
Journal: International urogynecology journal 20121001
Title: Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20121001
Title: Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Journal: Clinical therapeutics 20121001
Title: Emerging therapies: what's new is old and what's old is new.
Journal: The Canadian journal of urology 20121001
Title: An aryloxypropanolamine hβ3-adrenoceptor agonist as bladder smooth muscle relaxant.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120815
Title: Overactive bladder, under scrutiny, gets a new treatment.
Journal: Nature medicine 20120801
Title: Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
Journal: BJU international 20120701
Title: Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
Journal: BJU international 20120701
Title: [Pharmacological and clinical profile of mirabegron (Betanis(®)): a new therapeutic agent for overactive bladder].
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20120501
Title: Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.
Journal: Postgraduate medicine 20120501
Title: Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management.
Journal: Postgraduate medicine 20120501
Title: Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20120401
Title: Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120301
Title: Mirabegron for the treatment of overactive bladder.
Journal: Drugs of today (Barcelona, Spain : 1998) 20120101
Title: Mirabegron: a safety review.
Journal: Expert opinion on drug safety 20110301
Title: Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder.
Journal: Korean journal of urology 20101201
Title: Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.
Journal: IDrugs : the investigational drugs journal 20101001
Title: Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges.
Journal: Naunyn-Schmiedeberg's archives of pharmacology 20100801
Title: Effect of pre-contraction on β-adrenoceptor-mediated relaxation of rat urinary bladder.
Journal: World journal of urology 20091201
Title: Pharmacotherapy of the overactive bladder.
Journal: Discovery medicine 20091001
Title: Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
Journal: European urology 20090701
Title: Do gene polymorphisms alone or in combination affect the function of human beta3-adrenoceptors?
Journal: British journal of pharmacology 20090101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20080601
Title: Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.
Journal: The Journal of pharmacology and experimental therapeutics 20070501
Title: Relaxation of human detrusor muscle by selective beta-2 and beta-3 agonists and endogenous catecholamines.
Journal: Urology 20070401
Title: A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders.
Journal: The Journal of urology 20030801
Title: Beta3-adrenoceptors in human detrusor muscle.
Journal: Urology 20020501
Title: Takasu T, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)aminoethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007 May;321(2):642-7.
